Serina Therapeutics has secured $10 million in new funding to support the development of its lead product, SER-252 (POZ-apomorphine), for treating advanced Parkinson’s disease. The goal, according to a company press release, is to advance the candidate therapy toward a Phase 1 clinical trial in patients by…
The Parkinson’s disease therapy entacapone may disrupt the balance of microbes in the gut by starving them of iron, a study in healthy human fecal samples suggests. Supplementing patients with iron could prevent entacapone’s gastrointestinal side effects, but more research is needed to fully understand how the medication affects…
A framework called the neuronal alpha-synuclein disease integrated staging system (NSD-ISS) to stage patients in the early stretch of Parkinson’s disease, or who have yet to manifest symptoms, can help predict how quickly they may progress to clinically meaningful milestones. In a study led by Tanya Simuni, MD,…
A fellowship worth more than $1.2 million will fund research focused on improving the mobility of individuals living with Parkinson’s disease. The Advanced Fellowship from the National Institute for Health and Care Research was awarded to Rosie Morris, PhD, director of the Physiotherapy Innovation Laboratory at Northumbria University, in…
A small pump that’s worn as part of a teeth retainer can continuously release high daily doses of a paste formulation containing levodopa and carbidopa, easing motor symptoms for patients who need a steady supply of medication, such as those with advanced Parkinson’s disease, a study has found.
Supervised exercises at home may safely improve motor function and quality of life in people with mild to moderate Parkinson’s disease, a study in China suggests. The benefits were seen both with sessions conducted by a physical therapist at patients’ homes and with telerehabilitation using an application with predetermined…
A clinical trial testing the safety and tolerability of Brenig Therapeutics‘ BT-267, a potential disease-modifying therapy for Parkinson’s due to an unknown cause — known as idiopathic — or disease associated with LRRK2 gene mutations, has begun dosing healthy volunteers. Following this initial assessment — the first-in-human trial of…
The first six Parkinson’s disease patients given the investigational stem cell-based therapy TED-A9 in a clinical trial showed safety and an easing in their symptoms over one year of follow-up, the company developing the treatment, S.Biomedics, reported. A total of 12 adults, all diagnosed with Parkinson’s…
Researchers have developed a “double-hit” rat model of Parkinson’s disease wherein neurodegeneration is driven by both genetic susceptibility and environmental exposure to toxins. The rats were genetically engineered to accumulate human alpha-synuclein protein in the brain like existing models, but were also injected with an inflammation-inducing toxin. The animals…
HL192, an experimental oral therapy being developed to treat Parkinson’s disease, was tolerated well by healthy volunteers in a first-in-human clinical trial. The therapy’s developers — Nurron Pharmaceuticals, working in partnership with Hanall Biopharma and Daewoong Pharmaceutical — said they are planning a trial to…
Get regular updates to your inbox.